Informație de încredere. Sprijin real.

Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.

Spațiu publicitar disponibil — bannerul mare de susSpațiu publicitar disponibil — bannerul mare de sus

Explorează temele

Caută tot →

Sănătate mintală și neurodezvoltare

Afecțiuni neurologice

Articole și ghiduri recomandate

StudiuScleroză multiplăÎncredere bună26.06.2026

Circular RNAs: A New Approach to Multiple Sclerosis

This review examines the role of circular RNAs (a class of non-coding RNA) in multiple sclerosis pathogenesis, exploring how they regulate gene expression and immune function. CircRNAs influence neuroinflammation, neuronal damage, and microglial dysfunction, suggesting they could inform future diagnostic and therapeutic approaches to MS.

StudiuScleroză multiplăÎncredere bună23.06.2026

Machine Learning Analysis of Pupillary Light Reflex for Assessing Autonomic Dysfunction in Multiple Sclerosis

This study investigated pupillography combined with machine learning to detect autonomic dysfunction in patients with relapsing-remitting MS, achieving 85.7% accuracy on test data but lower performance (75% accuracy) on independent validation. The research demonstrates feasibility of pupil-based biomarkers for MS assessment while acknowledging generalizability challenges.

StudiuScleroză multiplăÎncredere înaltă23.06.2026

Residual cerebrospinal fluid inflammation persists during long-term natalizumab treatment in relapsing-remitting multiple sclerosis

This study measured 15 inflammatory biomarkers in cerebrospinal fluid from MS patients treated with natalizumab for varying durations, compared to untreated MS patients and healthy controls. While natalizumab significantly reduced most inflammatory markers, certain biomarkers including B cell maturation antigens and IL-10 remained elevated even after more than five years of treatment, suggesting incomplete suppression of intrathecal inflammation.

StudiuScleroză multiplăÎncredere înaltă23.06.2026

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial

A 12-month randomized controlled trial evaluated dulaglutide (a GLP-1 receptor agonist) as adjunctive therapy alongside natalizumab in 28 patients with relapsing-remitting MS, measuring neurofilament light chain levels, brain MRI changes, and functional outcomes. Treatment with dulaglutide significantly reduced weight, BMI, and body fat while improving glucose tolerance and potentially showing neuroprotective effects.